Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer

NCT03693170 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT03693170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03693170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 2
Overall status
Completed
Start date
January 17, 2019
Completion date
April 27, 2023
Enrollment
95 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600e-mutant metastatic colorectal cancer